Skip to main content

Table 5 Grade 3–4 toxicities per patient (all patients n = 40)

From: Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation

 

Grade 3–4 haematologic toxicity

Group

Neutropenia, no. pts (%)

Thrombocytopenia, no. pts (%)

Anemia, no. pts (%)

A

-

-

1 (2.5%)

B

-

-

-

C

6 (15%)

8 (20%)

2 (5%)

 

Grade 3–4 non-haematologic toxicity

Group

Hepatic, n. pts (%)

Mucositis, n. pts (%)

Nausea/vomiting, n. pts (%)

A

-

-

-

B

-

1 (2.5%)

-

C

2 (5%)

-

2 (5%)